The short version of human growth hormone fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-22 and is reviewed periodically as new material appears.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
== Retirement == On average, women in France receive pensions that are 41.7% lower than those received by men when considering only direct entitlement pensions. This gap is reduced to approximately 29% when accounting for child-related bonuses and survivor's pensions. Maternity leave daily allowances paid prior to 2012 are not included in the calculation of average annual income for pension purposes, which contributes to the pension gap.
=== Skin === One form the rashes take is called "heliotrope" (a purplish color) or lilac, but may also be red. It can occur around the eyes along with swelling, but also occurs on the upper chest or back what is called the "shawl" (around the neck) or "V-sign" above the breasts and may also occur on the face, upper arms, thighs, or hands. Another form the rash takes is called Gottron's sign, which is red or violet, sometimes scaly, slightly raised papules that erupt on any of the finger joints (the metacarpophalangeal joints or the interphalangeal joints). Gottron's papules may also be found over other bony prominences including the elbows, knees, or feet. All these rashes are made worse by exposure to sunlight, and are often very itchy, painful, and may bleed. If a person exhibits only skin findings characteristic of DM, without weakness or abnormal muscle enzymes, may be classified as having amyopathic or clinically amyopathic dermatomyositis (ADM), formerly known as "dermatomyositis sine myositis".
=== Cancer === PAHs have been linked to skin, lung, bladder, liver, and stomach cancers in well-established animal model studies. Specific compounds classified by various agencies as possible or probable human carcinogens are identified in the section "Regulation and Oversight" below.
Penis is majority collagen, so it typically has a gelatinous texture. The penis is typically byproduct in the meat industry. Penis has to be removed with care, at risk of rupturing the bladder or urethra and contaminating the carcass with urine.
== Research == Synovec's interests include both instrumentation and chemometrics, the science of using mathematical and statical tools to extract useful information from chemical data. His group were early adopters of comprehensive two-dimensional gas chromatography (GC×GC), a multidimensional separation technique. His group was the first to apply chemometric tools to GC×GC data, which had been largely used for spectroscopy up to that point. His group also introduced valve-based modulation techniques to GC×GC, which they have continued to develop, while early instruments used thermal modulation. Another focus of Synovec's lab is the development of comprehensive three-dimensional gas chromatography (GC3), a 3D extension of GC×GC which employs three separation columns and two modulators. His research lab has commercialized chemometric software for analyzing GC×GC data. He has been affiliated with the Center for Process Analysis and Control (formerly the Center for Process Analytical Chemistry). Synovec has graduated some 40 PhD students in addition to numerous Master's students and undergraduates. As of 2023 his publication record includes nearly 300 journal articles, with an h-index estimated to be in the 50s.
Sources: en.wikipedia.org
== General characteristics == Pseudomonas fluorescens has multiple flagella, an extremely versatile metabolism, and can be found in the soil and in water. It is an obligate aerobe, but certain strains are capable of using nitrate instead of oxygen as a final electron acceptor during cellular respiration. Optimal temperatures for growth of P. fluorescens are 25–30°C. It tests positive for the oxidase test, and is also a nonsaccharolytic bacterial species. Heat-stable lipases and proteases are produced by P. fluorescens and other similar pseudomonads. These enzymes cause milk to spoil, by causing bitterness, casein breakdown, and ropiness due to production of slime and coagulation of proteins.
In his February 2019 State of the State address, Newsom announced that, while work would continue on the 171-mile (275 km) Central Valley segment from Bakersfield to Merced, the rest of the system would be indefinitely postponed, citing cost overruns and delays. This and other actions created tension with the State Building and Construction Trades Council of California, a labor union representing 450,000 members.
The trypsin, once activated, can also cleave other trypsinogens as well as the precursors of other proteases such as chymotrypsin and carboxypeptidase to activate them. In bacteria, a similar strategy of employing an inactive zymogen or prezymogen is used. Subtilisin, which is produced by Bacillus subtilis, is produced as preprosubtilisin, and is released only if the signal peptide is cleaved and autocatalytic proteolytic activation has occurred.
Having united these two complex fragments, Still was able to complete the synthesis of monensin in three additional steps. First, hydrogenolysis of the benzyl group afforded the free primary alcohol under standard conditions. Next, cleavage of the triethylsilyl (TES) protecting groups was achieved in the presence of para-toluenesulfonic acid; the resulting free secondary alcohols then engaged the ketone in a spontaneous cyclization reaction to form the thermodynamic spiroketal linkage. Finally, hydrolysis of the methyl ester under basic conditions furnished the sodium salt of monensin, completing the synthesis of this challenging natural product.
Valerie Joy Beynon. For services to the community in Cobham, Surrey. Elizabeth Kay Billington. Chair, Kushti Bok and Vice-Chair, Dorset Council Gypsy Traveller Forum. For services to the Gypsy and Traveller Community in Dorset. William Archibald Bingham. Chair, Newcastle and Mourne Cancer Research Committee. For services to Cancer Research Fundraising in County Down. Chandra Shekhar Biyani. Consultant Urological Surgeon, Leeds Teaching Hospitals NHS Trust. For services to Medical Education. Reverend Christine Fiona Blackman. For services to the community in Reading, Berkshire. Derek John Bland. For services to the community in Northamptonshire. Roberta Vivian Lindsay Blyth. For services to the community in Roade, Northamptonshire. Winifred Patricia Bownes. Volunteer Coordinator, Cookstown Monday Club. For services to the community in Cookstown, County Tyrone. Mary Boyes. Cleaner, North Shore Academy, Stockton-on-Tees. For services to Education. John Robert Boyne-Aitken. For services to Heritage Crafts. Evelyn Lettita Bracey. For services to the community in Wantage, Oxfordshire. Paul Mark Brackley. Community First Responder, Oundle Community First Responders. For services to the community in Oundle and North Northamptonshire. Christopher Samuel Bradbury. For services to the community in Reedham, Norfolk. Moira Jeanette Brock. Founder and Principal, La Danse Fantastique. For services to Young People in Basildon, Essex. Anna Theresa Margaret Brown. For services to the NHS and to the community in the London Borough of Richmond-upon-Thames. Dennis Sydney Brown.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.